Tag: Alzheimer’s
FDA Head Asks for Investigation Into Alzheimer Disease Drug Approval
Request follows reports that Biogen and the FDA held off-the-books meetings before the drug's approval that may have violated FDA protocol
New Rx Instructions Tighten Use of Controversial Alzheimer Disease Drug
Major changes to prescribing instructions are rare, especially so soon after approval; change could curb the drug's use
Changes in Movement May Indicate Preclinical Alzheimer Disease
Changes in daytime fractal motor activity regulation may occur in women before cognitive symptoms of Alzheimer disease
House Committees to Investigate New Alzheimer Disease Drug Approval
FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness
Lilly to Seek FDA Approval for New Drug for Alzheimer Disease
Donanemab has already received a 'breakthrough therapy' designation from the FDA
Three FDA Advisers Quit Over Agency Approval of Aduhelm
Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness
FDA Approves Aduhelm for Alzheimer Disease
Agency says it has granted approval on the condition that drug maker Biogen conduct a new clinical trial
Donanemab Studied in Early Symptomatic Alzheimer Disease
Slightly less cognitive and functional decline seen with donanemab versus placebo at 76 weeks in phase 2 trial
AAN: Prior Psych Diagnosis Tied to Younger Age of Alzheimer Onset
Findings based on data from retrospective chart review of patients at tertiary specialty memory care center
Many Non-Whites Experience Discrimination in Alzheimer Disease Care
Overall, 36, 19, and 18 percent of Black, Hispanic, Asian Americans, respectively, believe discrimination is barrier to receiving care
